PRESS

NEWMEDS press

NEWMEDS in IMI JU Newsletter

28.10.2011

NEWMEDS in IMI JU Newsletter!

The IMI JU released the 7th edition - October 2011 of their newsletter today. NEWMEDS is listed under "News from the projects", informing the public about the results of NEWMEDS research into clinical trials.

For further information on the IMI JU Newsletter and the news on NEWMEDS, please visit:

The IMI JU website

Make Clinical Trials Shorter and Sexier, Study Suggests

07.09.2011

PARIS – Clinical trials can show meaningful results after 5 weeks, and many trials should include more women, according to findings from the NEWMEDS program.

NEWMEDS, which is short for Novel Methods Leading to New Medications in Depression and Schizophrenia, is a consortium of scientists from around the world. The consortium is funded by the Innovative Medicines Initiative, a large-scale partnership between the European Union (represented by the European Commission) and the pharmaceutical industry (represented by the European Federation of Pharmaceutical Industries and Associations), according to the NEWMEDS website.

by HEIDI SPLETE, Clinical Psychiatry News Digital Network

Reflections on the Innovative Medicines Initiative by Michel Goldman

The pharmaceutical industry is developing new collaborative models for drug development. This article discusses the experience so far of the Innovative Medicines Initiative, which is currently the largest public-private partnership that is dedicated to pharmaceutical innovation, highlighting lessons learned for the success of precompetitive consortia.

by Michel Goldman

Article_Goldman_IMIJU (0,14 MB)

NEWMEDS - International Collaboration amasses largest database to advance drug development in Depression and Schizophrenia

10.11.2010

International Collaboration amasses largest database to advance drug development in Depression and Schizophrenia
It is widely recognized that despite tremendous growth in biomedical knowledge, the deciphering of human genome and almost daily round of discoveries – the rate of development of new drugs has been slow. This is especially true in psychiatric disorders. One barrier to development has been the competitive relationship between rival companies and the other has been the limited exchange of science across the industry-academic divide.

NEWMEDS - International Collaboration amasses largest database to advance drug development in Depression and Schizophrenia_press_release (0,15 MB)